Bioanalysis: ADA Detection and High-Resolution Mass Spectrometry (HRMS)
Nexelis offers state-of-the-art, robust, bioanalytical testing to support your immunotherapy programs in a variety of matrices. To complement our protein science services, we offer HRMS assays for antibodies and antibody drug conjugates (ADCs). In addition to conventional LC-MS/MS methods, our, HRMS offers faster method development time and greater sensitivity.
In other applications of our bioanalytical platform, we provide assays to evaluate cytokine release syndrome following monoclonal antibody or CAR T-cell therapy.
Biomarkers: Cytokines, Growth Factors, and More
Nexelis offers numerous biomarkers related to cell-mediated immunity and the tumor environment. These can all be customized and validated as needed to support your studies. Biomarker assays we offer include BAFF (B-cell activating factor), BCMA (B-cell maturation antigen), CA-125, interferons, interleukins, M-CSF-1 (macrophage colony stimulating factor), MCP-1 (monocyte chemotactic protein-1), TGF β-1 (transforming growth factor β-1, multiple formats), and VCAM-1 (vascular adhesion molecule-1).
Early evaluation of the therapeutic potential of your immunomodulatory drug candidate is crucial for efficient development. We’ll help you gain better insights through analysis of immune cell subpopulations such as CD4+/CD8+. Readouts include multiplex flow cytometry, Luminex, ELISpot/Fluorospot, Incucyte®, and more. Our experts provide customized assays using high-quality human immune cells for in vitro screening of monoclonal and bispecific antibodies, proteins, peptides, RNA/DNA vaccines, viruses, etc.